Clinical trial
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging
NCT00565721 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging
- Lead sponsor
- GE Healthcare
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2007
- Completion date
- September 30, 2012
- Enrollment
- 33 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.